69 results
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
8:10am
if a dose is missed70% retention rate for adult patients Seizure-freedom rate is ˜ 72% when used adjunctively Patent exclusivity until at least May 2025
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
25 Sep 23
Regulation FD Disclosure
5:46pm
Long half-life, relieving the anxiety of breakthrough seizures if a dose is missed Retention rate70% for adult patients Seizure-freedom rate ˜ 72
8-K
EX-10.1
lgt1ormrxj 894n7as
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
EX-2.1
edntve3ej8uiz9
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.1
z3npp40xnr0s6f
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.2
l26p0r1d
12 Jul 22
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus
8:30am